Aeglea BioTherapeutics Announces Publication in Nature Medicine Demonstrating that Targeting Tumor Oxidative Stress with AEB3103 Suppresses Cancer Growth in Preclinical Models
21 nov. 2016 11h01 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results
09 nov. 2016 08h00 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors
08 nov. 2016 08h00 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present New Data on AEB3103 at American Society of Hematology (ASH) 58th Annual Meeting
03 nov. 2016 09h01 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Doses First Patients in Phase 1 Trial of AEB1102 for the Treatment of Arginase I Deficiency
15 sept. 2016 08h00 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Appoints Leading Experts to Inaugural Scientific Advisory Board
07 sept. 2016 08h00 HE
|
Aeglea Biotherapeutics
AUSTIN, Texas, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present at the 2016 Wells Fargo Healthcare Conference
01 sept. 2016 08h00 HE
|
Aeglea Biotherapeutics
AUSTIN, Texas, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies
29 août 2016 08h00 HE
|
Aeglea Biotherapeutics
AUSTIN, Texas, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results
09 août 2016 06h00 HE
|
Aeglea Biotherapeutics
AUSTIN, Texas, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer
18 juil. 2016 08h00 HE
|
Aeglea Biotherapeutics
--EMA Issued a Positive Opinion for Orphan Drug Designation for AEB1102-- --Initiated Two Phase 1 Clinical Trials of AEB1102 for Treatment of Hyperargininaemia and Hematological Malignancies-- ...